---
title: "Atrium Therapeutics, Inc. (RNA.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/RNA.US.md"
symbol: "RNA.US"
name: "Atrium Therapeutics, Inc."
industry: "Biotechnology"
datetime: "2026-05-20T17:28:37.486Z"
locales:
  - [en](https://longbridge.com/en/quote/RNA.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/RNA.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/RNA.US.md)
---

# Atrium Therapeutics, Inc. (RNA.US)

## Company Overview

Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company’s development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. The company was incorporated in 2025 and is headquartered in San Diego, California.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [atriumtherapeutics.com](https://atriumtherapeutics.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:13.000Z

**Overall: C (0.43)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 137 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 310.89% |  |
| Net Profit YoY | 84.11% |  |
| P/B Ratio | 0.86 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 200918809.70 |  |
| Revenue | 36680000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 0.00% | D |
| Profit Margin | -159.99% | E |
| Gross Margin | 45.00% | B |
| Revenue YoY | 310.89% | A |
| Net Profit YoY | 84.11% | A |
| Total Assets YoY | 0.00% | D |
| Net Assets YoY | 483.10% | A |
| Cash Flow Margin | 104.23% | C |
| OCF YoY | 310.89% | A |
| Turnover | 0.00 | E |
| Gearing Ratio | 19.93% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Atrium Therapeutics, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "310.89%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "84.11%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "0.86",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "200918809.70",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "36680000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "-159.99%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "45.00%",
          "rating": "B"
        },
        {
          "name": "Revenue YoY",
          "value": "310.89%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "84.11%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "483.10%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "104.23%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "310.89%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.00",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "19.93%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -3.42 | 320/386 | - | - | - |
| PB | 0.86 | 80/386 | 5.81 | 5.64 | 3.06 |
| PS (TTM) | 5.48 | 118/386 | 564.18 | 516.69 | 123.50 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-15T04:00:00.000Z

Total Analysts: **2**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 2 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 12.70 |
| Highest Target | 25.00 |
| Lowest Target | 25.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/RNA.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/RNA.US/norm.md)
- [Related News](https://longbridge.com/en/quote/RNA.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/RNA.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**